MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform. In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments.

At MaxCyte, our goal is to maximize the potential of cells to improve patients’ lives, and it is through collaborations such as this that we can achieve success. We look forward to supporting Lyell Immunopharma in its development of solid tumor treatments for patients with unmet needs.”

Doug Doerfler, President and CEO, MaxCyte

MaxCyte’s ExPERT instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Each of MaxCyte’s strategic partnerships generates pre-commercial milestone revenue and the vast majority include sales-based payments.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MaxCyte, Inc.. (2023, August 10). MaxCyte signs strategic platform license with Lyell Immunopharma. News-Medical. Retrieved on July 15, 2024 from

  • MLA

    MaxCyte, Inc.. "MaxCyte signs strategic platform license with Lyell Immunopharma". News-Medical. 15 July 2024. <>.

  • Chicago

    MaxCyte, Inc.. "MaxCyte signs strategic platform license with Lyell Immunopharma". News-Medical. (accessed July 15, 2024).

  • Harvard

    MaxCyte, Inc.. 2023. MaxCyte signs strategic platform license with Lyell Immunopharma. News-Medical, viewed 15 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients